Loading
A phase 2 trial of Bezuclastinib in systemic mastocytosis, run by Cogent Biosciences, Inc., active and no longer recruiting.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis is a phase 2 interventional study registered as NCT05186753 by Cogent Biosciences, Inc., with 237 participants planned, started 2022-06-27 and due to reach its primary completion in 2025-05-22. Interventions recorded: Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets. Conditions listed: SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bezuclastinib, Cogent Biosciences, Systemic mastocytosis.
Shares Bezuclastinib, Cogent Biosciences.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Bezuclastinib, Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/